Search results
Results from the WOW.Com Content Network
Ubrogepant, sold under the brand name Ubrelvy, is a medication used for the acute (immediate) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults. [4] [5] It is not indicated for the preventive treatment of migraine. [6] Ubrogepant is a small-molecule calcitonin gene-related peptide receptor antagonist.
This is a complete list of androgens/anabolic steroids (AAS) and formulations that are approved by the FDA Tooltip Food and Drug Administration and available in the United States. AAS like testosterone are used in androgen replacement therapy (ART), a form of hormone replacement therapy (HRT), and for other indications.
breast cancer: Herceptin 6981 7013 9 bevacizumab: colon cancer: Avastin 6847 6686 10 rituximab: non-Hodgkin's lymphoma: Rituxan, MabThera 6750 7298 11 rivaroxaban: anticoagulant: Xarelto 6589 6234 12 aflibercept: Eylea 6551 5830 13 infliximab: Remicade 5908 7152 14 Pneumococcal conjugate vaccine: Prevnar 13 Prevenar 13 5802 5601 15 ustekinumab ...
Platinum-based drugs, which includes cisplatin and carboplatin, are prescribed to an estimated 10% to 20% of all cancer patients, according to the National Cancer Institute. They are used for a ...
For premium support please call: 800-290-4726 more ways to reach us
By 2011 the oral medications for cancer patients represented approximately 35% of cancer medications. Prior to the increase in cancer oral drugs community cancer centers were used to managing office-administered chemotherapy treatments. At that time "the majority of community oncology practices were unfamiliar with the process of prescribing ...
BeiGene, Ltd. is a multinational oncology company. [3] It specializes in the development of drugs for cancer treatment. [4] Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has offices in North America, Europe, South America, Asia and Australia.
In September 2018, galcanezumab was approved in the United States for the preventive treatment of migraine in adults. [9] [10] The FDA granted the approval of Emgality to Eli Lilly. [9] [10] In November 2018, galcanezumab was approved for use in the European Union for the prophylaxis of migraine in adults who have at least four migraine days ...